SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma gets USFDA nod for Cefadroxil Oral Suspension

26 Apr 2013 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cefadroxil for Oral Suspension USP 250mg/5mL and 500mg/5mL.

Cefadroxil for Oral Suspension USP, 250mg/5mL and 500mg/5mL is the generic equivalents of Warner Chilcott Company, Inc’s Duricef for Oral Suspension 250mg/5mL and 500mg/5mL. Cefadroxil is a cephalosporin antibiotic indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms such as urinary tract infections caused by E.coli, P.mirabilis, and Klebsiella species; skin and skin structure infections caused by staphylococci and/or streptococci; Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.

The product has been approved out of Unit VI Cephalosporin formulations manufacturing facility in Hyderabad, India. The company now has a total of 187 ANDA approvals (160 Final approvals including 4 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×